+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endometriosis - Pipeline Review, H2 2018

  • ID: 4621779
  • Drug Pipelines
  • 135 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • ElexoPharm GmbH
  • Enteris BioPharma Inc
  • Forendo Pharma Ltd
  • Luye Pharma Group Ltd
  • Ogeda SA
  • MORE
Endometriosis - Pipeline Review, H2 2018

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Pipeline Review, H2 2018, provides an overview of the Endometriosis (Women's Health) pipeline landscape.

Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. Risk factors age, uterine abnormalities, history of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins.

Report Highlights

This latest pipeline guide Endometriosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Endometriosis (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometriosis (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 10, 15, 2, 12, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 3 molecules, respectively.

Endometriosis (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Endometriosis (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Endometriosis (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Endometriosis (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Endometriosis (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Endometriosis (Women's Health)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Endometriosis (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Endometriosis (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • ElexoPharm GmbH
  • Enteris BioPharma Inc
  • Forendo Pharma Ltd
  • Luye Pharma Group Ltd
  • Ogeda SA
  • MORE
Introduction

Endometriosis - Overview

Endometriosis - Therapeutics Development

Endometriosis - Therapeutics Assessment

Endometriosis - Companies Involved in Therapeutics Development

Endometriosis - Drug Profiles

Endometriosis - Dormant Projects

Endometriosis - Discontinued Products

Endometriosis - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Endometriosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Endometriosis - Pipeline by Addex Therapeutics Ltd, H2 2018

Endometriosis - Pipeline by Auritec Pharmaceuticals Inc, H2 2018

Endometriosis - Pipeline by Bayer AG, H2 2018

Endometriosis - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018

Endometriosis - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018

Endometriosis - Pipeline by ElexoPharm GmbH, H2 2018

Endometriosis - Pipeline by EndoCeutics Inc, H2 2018

Endometriosis - Pipeline by Enteris BioPharma Inc, H2 2018

Endometriosis - Pipeline by Evotec AG, H2 2018

Endometriosis - Pipeline by Forendo Pharma Ltd, H2 2018

Endometriosis - Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2018

Endometriosis - Pipeline by Immunitor Inc, H2 2018

Endometriosis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018

Endometriosis - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2018

Endometriosis - Pipeline by Luye Pharma Group Ltd, H2 2018

Endometriosis - Pipeline by Nippon Shinyaku Co Ltd, H2 2018

Endometriosis - Pipeline by Ogeda SA, H2 2018

Endometriosis - Pipeline by Philogen SpA, H2 2018

Endometriosis - Pipeline by Predictive Therapeutics LLC, H2 2018

Endometriosis - Pipeline by Repros Therapeutics Inc, H2 2018

Endometriosis - Pipeline by SK Chemicals Co Ltd, H2 2018

Endometriosis - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Endometriosis - Pipeline by ValiRx Plc, H2 2018

Endometriosis - Pipeline by Viramal Ltd, H2 2018

Endometriosis - Dormant Projects, H2 2018

Endometriosis - Dormant Projects, H2 2018 (Contd..1), H2 2018

Endometriosis - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Endometriosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Addex Therapeutics Ltd
  • Auritec Pharmaceuticals Inc
  • Bayer AG
  • Chugai Pharmaceutical Co Ltd
  • Daewoong Pharmaceutical Co Ltd
  • ElexoPharm GmbH
  • EndoCeutics Inc
  • Enteris BioPharma Inc
  • Evotec AG
  • Forendo Pharma Ltd
  • GeneScience Pharmaceuticals Co Ltd
  • Immunitor Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Kissei Pharmaceutical Co Ltd
  • Luye Pharma Group Ltd
  • Nippon Shinyaku Co Ltd
  • Ogeda SA
  • Philogen SpA
  • Predictive Therapeutics LLC
  • Repros Therapeutics Inc
  • SK Chemicals Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • ValiRx Plc
  • Viramal Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4621779
Adroll
adroll